A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models

Zhang, Jian; Lai, Weijie; Li, Qiang; Ye, Yu; Jin, Jin; Guo, Wan; Zhou, Xiumei; Liu, Xinyuan; Wang, Yigang

doi:10.1016/j.bbrc.2017.07.041

Cited by 54 publications

(36 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GSK‐3beta suppresses HCC cell dissociation in vitro by upregulating epithelial junction proteins and inhibiting the Wnt/β‐catenin signaling pathway . A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer‐stem like cell growth via metastasis, apoptosis, and autophagy in HCC models . Agkihpin, a novel SVAE may inhibit the migration and invasion of liver cancer cells associated with the inversion of EMT induced by the Wnt/β‐catenin signaling inhibition .…”

Section: Discussionmentioning

confidence: 99%

“…The canonical Wnt/β-catenin signaling pathway plays an important role in EMT and metastasis. 11,12 The expression of Wnt2 is implicated in activating/stabilizing β-catenin, similar to other canonical (β-catenin-mediated) Wnt ligands. [13][14][15] Frizzled 4, an essential receptor in the Wnt/β-catenin signaling.…”

Section: Crnde Modulated Wnt/β-catenin Signaling In Hcc Cellsmentioning

confidence: 99%

See 1 more Smart Citation

LncRNA CRNDE promotes the epithelial‐mesenchymal transition of hepatocellular carcinoma cells via enhancing the Wnt/β‐catenin signaling pathway

Zhū

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Colorectal neoplasia differentially expressed (CRNDE) is a significantly upregulated long noncoding RNA in hepatocellular carcinoma (HCC). CRNDE could promote cell proliferation, migration, and invasion, while its molecular mechanisms were still largely unclear. In this study, we investigated the expression and function of CRNDE. CRNDE was significantly upregulated in tumor tissues compared with adjacent normal tissues. In vitro, we revealed that knockdown of CRNDE inhibited cell proliferation, migration, and cell invasion capacities in HCC. Animal studies indicated that CRNDE knockdown represses both growth and metastasis of HCC tumors in vivo. Moreover, knockdown of CRNDE suppressed the cell epithelial‐mesenchymal transition (EMT) process by increasing the expression of E‐cadherin and ZO‐1, whereas, decreasing the expression of N‐cadherin, slug, twist, and vimentin in HCC cells. We also revealed that knockdown of CRNDE suppressed the Wnt/β‐catenin signaling in HCC. Thus, CRNDE could modulate EMT of HCC cells and knockdown of CRNDE impaired the mesenchymal properties. CRNDE increased invasion of HCC cells might be through activating the Wnt/β‐catenin signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Crnde Modulated Wnt/β-catenin Signaling In Hcc Cellsmentioning

confidence: 99%

LncRNA CRNDE promotes the epithelial‐mesenchymal transition of hepatocellular carcinoma cells via enhancing the Wnt/β‐catenin signaling pathway

Zhū

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…In the course of developing replication‐defective rAd and HSV recombinant vectors, certain tumor cells showed a permissiveness for viral replication. That is, these tumor cells showed a predilection for supporting viral replication of adenoviruses, herpesviruses, measles viruses, and others (18, 19, 24‐26, 50, 52, 53, 56‐71). Although these oncolytic viruses are not exclusively selective for tumor cells, they show the properties of a “silver bullet,” replicating in and damaging tumor cells selectively over normal cells.…”

Section: Established Gene Therapy Vector Approachesmentioning

confidence: 99%

“…Those studies indicated that rAd vector gene transfer was generally transient and was associated with an innate immune (or inflammatory) response and with adaptive immune responses to viral genes present in first-and second-generation vectors (13)(14)(15)(16)(17). Subsequently, these characteristics proved to be useful in the context of gene therapy for malignancy, particularly in the context of inducing multivalent immune responses to tumor antigens (18)(19)(20)(21)(22)(23)(24)(25)(26).…”

Section: Recombinant Adenovirus Vectorsmentioning

confidence: 99%

The rapidly evolving state of gene therapy

Gruntman

Flotte

2018

FASEB j.

View full text Add to dashboard Cite

Gene therapy is emerging as a viable option for clinical therapy of monogenic disorders and other genetically defined diseases, with approved gene therapies available in Europe and newly approved gene therapies in the United States. In the past 10 years, gene therapy has moved from a distant possibility, even in the minds of much of the scientific community, to being widely realized as a valuable therapeutic tool with wide‐ranging potential. The U.S. Food and Drug Administration has recently approved Luxturna (Spark Therapeutics Inc, Philadelphia, PA, USA), a recombinant adeno‐associated virus (rAAV) 2 gene therapy for one type of Leber congenital amaurosis 2 (1, 2). The European Medicines Agency (EMA) has approved 3 recombinant viral vector products: Glybera (UniQure, Amsterdam, The Netherlands), an rAAV vector for lipoprotein lipase deficiency; Strimvelis (Glaxo Smith‐Kline, Brentford, United Kingdom), an ex vivo gammaretrovirus‐based therapy for patients with adenosine deaminase‐deficient severe combined immune deficiency (ADA‐SCID); and Kymriah (Novartis, Basel, Switzerland), an ex vivo lentivirus‐based therapy to engineer autologous chimeric antigen‐receptor T (CAR‐T) cells targeting CD19–positive cells in acute lymphoblastic leukemia. These examples will be followed by the clinical approval of other gene therapy products as this field matures. In this review we provide an overview of the state of gene therapy by discussing where the field stands with respect to the different gene therapy vector platforms and the types of therapies that are available.— Gruntman, A. M., Flotte, T. R. The rapidly evolving state of gene therapy. FASEB J. 32, 1733–1740 (2018). http://www.fasebj.org

show abstract

“…Hepatocellular carcinoma (HCC) is the third cancer‐related death in the world . Despite the improvement of diagnostic approaches and treatment strategies, the 5‐year survival rate of HCC is still poor .…”

Section: Introductionmentioning

confidence: 99%